



## Products fact sheet

APR's product portfolio is the result of our powerful expertise in the development of innovative patient-centric solutions. Our products are mostly based on proprietary science and technology that provide unique treatment options for patients and healthcare professionals by addressing their unmet needs.

Some of the latest product launches include the following **prescription and consumer healthcare products and technologies**:

### **Physiomimic™ Technology**

A drug delivery Technology platform, developed and patented by APR, which has been engineered to allow a **physiological absorption of amino acids**, mimicking the absorption kinetics of dietary proteins. The Physiomimic™ Technology finds its distinctive values in **clinical positive consequences** in aminoacidopathies management connected with the prolonged absorption of the amino acids as well as in a **remarkable masking effect of the amino acid taste and odor**, potentially supporting patients' compliance. A robust development plan, including both pre-clinical and clinical studies, is underway to reinforce the scientific profile of this proprietary technology.

An **innovative medical food for phenylketonuria (PKU)** has been developed based on the Physiomimic™ Technology and other formulations are being evaluated to convey such benefits to other aminoacidopathies.

### **Nexodyn®**

Nexodyn® AOS (AcidOxidizing Solution) is the first **Active Wound Cleanser that creates an ideal wound Microenvironment**, thus sustaining the physiological wound healing process and favoring an optimized lesion closure, especially in chronic wounds management. Nexodyn® has been developed based on APR's proprietary and patented Nano-technology TEHCLO® enabling the production pure and stable HClO (Hypochlorous Acid) in a liquid carrier, where all the most important parameters are balanced and optimized in order to obtain one of the best formulation in terms of efficacy and safety so maximizing its **anti-microbial, anti-inflammatory and tissue regenerating properties**.

Nexodyn® AOS AcidOxidizing Solution contains hypochlorous acid (HClO), a known antimicrobial agent acting as a preservative by **inhibiting the growth of microorganisms within the solution, and preventing wound contamination** by exerting a local antimicrobial effect on the wound surface.

A wide array of non-clinical experiments and clinical observations suggest Nexodyn® AOS spray solution to act as a **valid support to the activation of the physiological processes that restart wound healing**, in presence of a favorable safety and tolerability profile.

#### Contacts:

APR Applied Pharma Research s.a.,  
Paolo Galfetti, CEO - T: +41 91 6957020 or email to [paolo.galfetti@apr.ch](mailto:paolo.galfetti@apr.ch)  
Havas PR Milan - Press Office  
Sara Bernabovi - T: +39 02 85457032 or email to [sara.bernabovi@havaspr.com](mailto:sara.bernabovi@havaspr.com)



### Halykoo®

Halykoo®, the babies' healthcare expert, is the **first global brand offering the most comprehensive range of consumer healthcare products**. It matches formulations specifically focused on each of the main stages of children's growth, since birth, with smart and innovative deliveries intended to simplify their use for parents and reduce the hassle for babies.

The product range has been carefully developed to solve the main daily babies' healthcare discomforts in the major therapeutic areas for turnover such as skin care, cough & cold, eye, ear & mouth and food supplementation. As of today, the portfolio includes over 18 already developed products and 10 additional products are under development to be finalized in 2018.

**Conceived and formulated applying the value of Swiss pharmaceutical expertise**, Halykoo provides science-driven pediatric solutions that perfectly combine smart deliveries, thanks to the application of the **pharmaceutical technology knowledge**, with **advanced formulations**, balanced on the physiological babies' needs.

### SwitzAge®

SwitzAge® is the first **100% Swiss Made Nutraceutical range**, which aim at enhancing adult and mature people quality of life by targeting healthcare needs to enable them to realize their potential for physical, social and mental wellbeing throughout the life course.

The range is currently made of 8 food supplements, whose development was inspired from a **patient-centric and holistic health approach** to provide the right answers for body and mind enhancement focusing on the physiological differences between man and lady.

Each SwitzAge® product is the result of the **Swiss high-quality pharmaceutical research, applied to healthy ageing**: products formulations contain a balanced mix of natural ingredients, vitamins and minerals and they are totally lactose, gluten and sugars free. Formulated in user-friendly pharmaceutical form, mono-dose effervescent powder, chewable tablets and soft gel capsules, for an easier administration whilst sales packs cover one month of treatment.

### Diclofenac Immediate Release

Diclofenac is a non-steroidal anti-inflammatory drug (NSAID), indicated for the management of short-term acute painful conditions and migraine. For EU and Extra-EU Countries is indicated for short term treatment of acute painful, inflammation conditions and migraine attacks. In the US and Canada it is indicated for acute treatment of migraine attacks with or without aura. Recently, it has been established as **"effective" (Level A)** therapy by the **AHS (America Headache Society)**, following an evidence-based assessment via a systematic review of Class I studies.

**Immediate Release Technology (IRT)**, developed and patented by APR, is characterized by the unique blending of excipients and in particular a special ratio between diclofenac and bicarbonate, that create a micro-environmental at gastro-intestinal level, to ensure more rapid and regular absorption and faster onset

#### Contacts:

APR Applied Pharma Research s.a.,  
Paolo Galfetti, CEO - T: +41 91 6957020 or email to [paolo.galfetti@apr.ch](mailto:paolo.galfetti@apr.ch)  
Havas PR Milan - Press Office  
Sara Bernabovi - T: +39 02 85457032 or email to [sara.bernabovi@havaspr.com](mailto:sara.bernabovi@havaspr.com)



of action of diclofenac in APR formulations (powder for oral solution, tablets and oral solution) compared with conventional preparations.

APR's Immediate Release Technology (IRT), applied to Diclofenac solutions, is currently licensed and commercialized under the following brands:

- **Cambia**, registered trademark of **Depomed**, exclusively licensed in **USA and Canada**.
- **Voltfast**, registered trademark of Novartis AG, licensed internationally.

### **Ondansetron ODF**

Ondansetron is indicated for the prevention and treatment of chemo and radiotherapy induced nausea and vomiting (CINV and RINV), and for the prevention and treatment of post-operative nausea and vomiting (PONV). Ondansetron **OroDispersible Film/Orally Disintegrating Film (ODF)**, is approved in EU and US (for pediatric populations) and has been developed by APR, in cooperation with MonoSol Rx for the USA market and Labtec TESA outside USA respectively. The ODF technology - with its **ultra-thin, oral dissolvable film**, composed of a water-soluble polymer - aims to offer a **better compliance and safety** than oral dispersible tablets.

It has a **bioequivalence** to Ondansetron ODT, thanks to a proven, non-sedating efficacy in both fast and fed conditions.

APR's Ondansetron ODF is currently licensed and commercialized under the following brands:

- **SETOFILM**, registered trademark of APR Applied Pharma s.a., exclusively licensed to the Norgine group of companies in the EU
- **Ondissolve ODF**, registered trademark of Takeda Canada, exclusively licensed in Canada
- **Zuplenz**, registered trademark of Midatech Pharma Plc, exclusively licensed in USA.

#### Contacts:

APR Applied Pharma Research s.a.,  
Paolo Galfetti, CEO - T: +41 91 6957020 or email to [paolo.galfetti@apr.ch](mailto:paolo.galfetti@apr.ch)  
Havas PR Milan - Press Office  
Sara Bernabovi - T: +39 02 85457032 or email to [sara.bernabovi@havaspr.com](mailto:sara.bernabovi@havaspr.com)